Multicenter clinical trial of ultrasmall superparamagnetic iron oxide in the evaluation of mediastinal lymph nodes in patients with primary lung carcinoma

Journal of Magnetic Resonance Imaging

Volumn 10, Issue 3, 1999, Pages 468-473

  Nguyen, Bao C ^a   Stanford, William ^b,e   Thompson, Brad H ^a   Rossi, Nicholas P ^a   Kernstine, Kemp H ^a   Kern, Jeffrey A ^a   Robinson, Robert A ^a   Amorosa, Judith K ^b   Mammone, Joseph F ^c   Outwater, Eric K ^d  

^a UNIVERSITY OF IOWA   (United States)

^b ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^c RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^d THOMAS JEFFERSON UNIVERSITY   (United States)

^e UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

Contrast media; Mediastinal lymph nodes; Metastatic lung cancer; Ultrasmall superparamagnetic iron oxide particles

Indexed keywords

CONTRAST MEDIUM; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTRAST ENHANCEMENT; DIAGNOSTIC IMAGING; DIFFERENTIAL DIAGNOSIS; FEMALE; HISTOPATHOLOGY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG CARCINOMA; LUNG NON SMALL CELL CANCER; MALE; MEDIASTINUM LYMPH NODE; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; CONTRAST MEDIA; FEMALE; HUMANS; IMAGE ENHANCEMENT; IRON; LUNG NEOPLASMS; LYMPH NODES; LYMPHATIC METASTASIS; MAGNETIC RESONANCE IMAGING; MALE; MEDIASTINUM; MIDDLE AGED; NEOPLASM STAGING; OXIDES; PARTICLE SIZE; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY;

EID: 0032874777     PISSN: 10531807     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1522-2586(199909)10:3<468::AID-JMRI31>3.0.CO;2-I     Document Type: Article

References (17)

1. Staples CA, Muller ML, Miller RR, et al. Medlastinal nodes in bronchogenic carcinoma: comparison between CT and mediastinoscopy. Radiology 1988;167:367-372.
2. McLoud TC, Bourgouin PM, Greenberg RW, et al. Bronchogenic carcinoma: analysis of staging in the mediastinum with CT by correlative lymph node mapping and sampling. Radiology 1992;182: 319-323.
3. Van Shil PEY, Van Hee RHGG, Shoofs ELG. The value of mediastinoscopy in preoperative staging of bronchogenic carcinoma. J Thorac Cardiovasc Surg 1989;97:240-244.
4. Yokoi K, Okuyama A, Mori K, et al. Mediastinal lymph node metastasis for lung cancer: evaluation with T1-201 SPECT-comparison with CT. Radiology 1994;192:813-817.
5. Van dongen GAMS, Leverstein H, Roos JC, et al. Radioimmunoscintigraphy of head and neck cancer using 99m-Tc-labeled monoclonal antibody E48 F(ab)2. Cancer Res 1992;52:2569-2574.
6. Guimaraes R, Clement O, Bittoun J. et al. MR lymphography with superparamagnetic iron nanoparticles in rats: pathologic basis for contrast enhancement. AJR 1994;162:201-207.
7. Stark D, Weissleder R, Elizondo G, et al. Superparamagnetic iron oxide: clinical application as a contrast agent for MR imaging of the liver. Radiology 1988;168:297-301.
8. Weissleder R, Elizondo G, Josphson L, et al. Experimental lymph node metastases: enhanced detection with MR lymphography. Radiology 1989;171:835-839.
9. Anzai Y, McLachlan S, Morris M, et al. Dextran-coated superparamagnetic iron oxide: the first human use of a new contrast agent for assessing lymph nodes in the head and neck. Am J Neuroradiol 1994;15:87-94.
10. Anzai Y, McLachlan S, Morris M, Saxton R, Lufkin RB. Dextran-coated superparamagnetic iron oxide: an MR contrast agent for assessing lymph nodes in the head and neck. AJNR 1994;15:87-94.
11. Anzai Y, Blakewell KE, Hirschowitz SI, et al. Initial clinical experience with dextran-coated superparamagnetic iron oxide for detection of lymph node metastases in patients with head and neck cancer. Radiology 1994;192:709-715.
12. Bellin MF, Roy C, Kinkel K, et al. Lymph node metastases: safety and effectiveness of MR Imaging with ultrasmall superparamagnetic iron oxide particles-initial clinical experience. Radiology 1998; 207:799-808.
13. McLachlan S, Morris MR, Lucas MA, et al. Phase I clinical evaluation of a new iron oxide MR contrast agent. J Magn Reson Imaging 1994;4:301-307.
14. Weissleder R, Elizondo G, Wittenberg J, et al. Ultrasmall superparamagnetic iron oxide: an intravenous contrast agent for assessing lymph nodes with MR imaging. Radiology 1990;175:494-498.
15. Saini S, Edelman RR, Sharma P, et al. Blood-pool MR contrast material for detection and characterization of focal hepatic lesions: initial clinical experience with ultrasmall superparamagnetic iron oxide (AMI-227). AJR 1995;164:1147-1152.
16. Vogel TJ, Hammersting R, Schwarz W, et al. Superparamagnetic iron oxide-enhanced versus gadolinium-enhanced MR imaging for differential diagnosis of focal liver lesion. Radiology 1996;198:881-887.
17. Weissleder R, Elizondo G, Wittenberg J, et al. Ultrasmall superparamagnetic iron oxide: characterization of a new class of contrast agents for MR imaging. Radiology 1990;175:489-493.